A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Recruiting

Early Phase 1 — The very first tests in people. Usually just a handful of volunteers, to check the treatment is safe enough to keep studying.

Trial locations(1 site)

China

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang